Active Warming Versus Non Active Warming During Caesarean Section for Preventing Neonatal Hypothermia (NeoHyp)
Neonatal Hypothermia
About this trial
This is an interventional prevention trial for Neonatal Hypothermia focused on measuring caesarean section, neonatal hypothermia, maternal hypothermia, active warming, skin-to-skin contact
Eligibility Criteria
Inclusion Criteria:
In order for women and their new-borns to be eligible to participate in the study they should be;
- Aged 18 years or over
- Able to provide informed consent for themselves and their babies
- Who have a singleton pregnancy between 37+0 and 41+6 weeks gestation
- Whose foetus/new-born is alive/born alive, and has no risk factors such as congenital or cardiovascular anomalies (see Appendix 2, TSRF)
- Who receive spinal or combined spinal anaesthesia for their caesarean section
- Have an elective CS
- Who are willing and able to perform skin-to-skin contact
Exclusion Criteria:
Women will be excluded from this study if they;
- Have pyrexia (> 37.5C on admission to ward)
- Have a maternal medical disease (ie. Spinal abnormalities, coagulation abnormalities, maternal serology positive, congestive heart failure, severe renal function impairment)
- Have general anaesthesia
- Have a baby who has a congenital anomaly (ie. Spina bifida, anencephaly, hydrocephaly, cardiovascular anomalies, anomalies of nervous system, defects of anterior abdominal wall)
- Have a baby who has abnormal Doppler artery velocimetry
- Have a stillbirth baby
- Have a recent USS estimating the fetal weight less than 2000g
Sites / Locations
- Rotunda Hospital
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Control Group
active warming group
Women randomised to the control group will receive the hospital's current standard of care which is the peri-operative administration of room-temperature (25°C) IV fluids (Hartman's solution) started before the insertion of regional anaesthesia and continued until the transfer of the woman to the postnatal ward.
Women randomised in the intervention group will recieve warm IV fluids. The IV fluids (Hartman's solution) will be warmed to 39°C with the use of Hotline™ device.